592 related articles for article (PubMed ID: 28689430)
1. Current and future therapies for gout.
Pascart T; Richette P
Expert Opin Pharmacother; 2017 Aug; 18(12):1201-1211. PubMed ID: 28689430
[TBL] [Abstract][Full Text] [Related]
2. Updates on the treatment of gout, including a review of updated treatment guidelines and use of small molecule therapies for difficult-to-treat gout and gout flares.
Soskind R; Abazia DT; Bridgeman MB
Expert Opin Pharmacother; 2017 Aug; 18(11):1115-1125. PubMed ID: 28658988
[TBL] [Abstract][Full Text] [Related]
3. Lesinurad: A Review in Hyperuricaemia of Gout.
Deeks ED
Drugs Aging; 2017 May; 34(5):401-410. PubMed ID: 28425024
[TBL] [Abstract][Full Text] [Related]
4. Limitations of the Current Standards of Care for Treating Gout and Crystal Deposition in the Primary Care Setting: A Review.
Keenan RT
Clin Ther; 2017 Feb; 39(2):430-441. PubMed ID: 28089200
[TBL] [Abstract][Full Text] [Related]
5. Potency on lowering serum uric acid in gout patients: a pooled analysis of registrative studies comparing febuxostat vs. allopurinol.
Cutolo M; Cimmino MA; Perez-Ruiz F
Eur Rev Med Pharmacol Sci; 2017 Sep; 21(18):4186-4195. PubMed ID: 29028079
[TBL] [Abstract][Full Text] [Related]
6. Novel uricosurics.
Bardin T; Richette P
Rheumatology (Oxford); 2018 Jan; 57(suppl_1):i42-i46. PubMed ID: 29272511
[TBL] [Abstract][Full Text] [Related]
7. Pharmacodynamic, pharmacokinetic and tolerability evaluation of concomitant administration of lesinurad and febuxostat in gout patients with hyperuricaemia.
Fleischmann R; Kerr B; Yeh LT; Suster M; Shen Z; Polvent E; Hingorani V; Quart B; Manhard K; Miner JN; Baumgartner S;
Rheumatology (Oxford); 2014 Dec; 53(12):2167-74. PubMed ID: 24509406
[TBL] [Abstract][Full Text] [Related]
8. An allopurinol-controlled, multicenter, randomized, double-blind, parallel between-group, comparative study of febuxostat in Chinese patients with gout and hyperuricemia.
Huang X; Du H; Gu J; Zhao D; Jiang L; Li X; Zuo X; Liu Y; Li Z; Li X; Zhu P; Li J; Zhang Z; Huang A; Zhang Y; Bao C
Int J Rheum Dis; 2014 Jul; 17(6):679-86. PubMed ID: 24467549
[TBL] [Abstract][Full Text] [Related]
9. Gout: state of the art after a decade of developments.
Pascart T; Lioté F
Rheumatology (Oxford); 2019 Jan; 58(1):27-44. PubMed ID: 29547895
[TBL] [Abstract][Full Text] [Related]
10. Prophylaxis for acute gout flares after initiation of urate-lowering therapy.
Latourte A; Bardin T; Richette P
Rheumatology (Oxford); 2014 Nov; 53(11):1920-6. PubMed ID: 24758886
[TBL] [Abstract][Full Text] [Related]
11. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout.
Becker MA; Schumacher HR; MacDonald PA; Lloyd E; Lademacher C
J Rheumatol; 2009 Jun; 36(6):1273-82. PubMed ID: 19286847
[TBL] [Abstract][Full Text] [Related]
12. Expert opinion on emerging urate-lowering therapies.
Stamp LK; Merriman TR; Singh JA
Expert Opin Emerg Drugs; 2018 Sep; 23(3):201-209. PubMed ID: 30244605
[TBL] [Abstract][Full Text] [Related]
13. Febuxostat.
Hair PI; McCormack PL; Keating GM
Drugs; 2008; 68(13):1865-74. PubMed ID: 18729537
[TBL] [Abstract][Full Text] [Related]
14. Febuxostat: a review of its use in the treatment of hyperuricaemia in patients with gout.
Frampton JE
Drugs; 2015 Mar; 75(4):427-38. PubMed ID: 25724536
[TBL] [Abstract][Full Text] [Related]
15. Lesinurad for the treatment of hyperuricaemia in people with gout.
Robinson PC; Dalbeth N
Expert Opin Pharmacother; 2017 Dec; 18(17):1875-1881. PubMed ID: 29103339
[TBL] [Abstract][Full Text] [Related]
16. Febuxostat: a selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout.
Ernst ME; Fravel MA
Clin Ther; 2009 Nov; 31(11):2503-18. PubMed ID: 20109996
[TBL] [Abstract][Full Text] [Related]
17. Pharmacotherapeutic management of gout in patients with cardiac disease.
Chan CW; Yap YN
Expert Opin Pharmacother; 2018 Dec; 19(18):2011-2018. PubMed ID: 30345832
[TBL] [Abstract][Full Text] [Related]
18. Febuxostat compared with allopurinol in patients with hyperuricemia and gout.
Becker MA; Schumacher HR; Wortmann RL; MacDonald PA; Eustace D; Palo WA; Streit J; Joseph-Ridge N
N Engl J Med; 2005 Dec; 353(23):2450-61. PubMed ID: 16339094
[TBL] [Abstract][Full Text] [Related]
19. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.
Schumacher HR; Becker MA; Wortmann RL; Macdonald PA; Hunt B; Streit J; Lademacher C; Joseph-Ridge N
Arthritis Rheum; 2008 Nov; 59(11):1540-8. PubMed ID: 18975369
[TBL] [Abstract][Full Text] [Related]
20. Febuxostat for the treatment of hyperuricaemia in people with gout: a single technology appraisal.
Stevenson M; Pandor A
Health Technol Assess; 2009 Oct; 13 Suppl 3():37-42. PubMed ID: 19846027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
